SA516370751B1 - تركيبات تشمل مجموعات متغايرة من بروتينات xa لعامل تخثر آدمي تخليقي - Google Patents
تركيبات تشمل مجموعات متغايرة من بروتينات xa لعامل تخثر آدمي تخليقي Download PDFInfo
- Publication number
- SA516370751B1 SA516370751B1 SA516370751A SA516370751A SA516370751B1 SA 516370751 B1 SA516370751 B1 SA 516370751B1 SA 516370751 A SA516370751 A SA 516370751A SA 516370751 A SA516370751 A SA 516370751A SA 516370751 B1 SA516370751 B1 SA 516370751B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- protein
- fxa
- clotting factor
- light chain
- factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Water Supply & Treatment (AREA)
- Toxicology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881834P | 2013-09-24 | 2013-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA516370751B1 true SA516370751B1 (ar) | 2018-04-05 |
Family
ID=51844797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA516370751A SA516370751B1 (ar) | 2013-09-24 | 2016-03-17 | تركيبات تشمل مجموعات متغايرة من بروتينات xa لعامل تخثر آدمي تخليقي |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9757434B2 (enExample) |
| EP (1) | EP3049434A1 (enExample) |
| JP (1) | JP6429885B2 (enExample) |
| KR (1) | KR101988705B1 (enExample) |
| CN (2) | CN105579468A (enExample) |
| AR (1) | AR097732A1 (enExample) |
| AU (1) | AU2014326257B2 (enExample) |
| BR (1) | BR112016005899A8 (enExample) |
| CA (1) | CA2924981C (enExample) |
| HK (1) | HK1218760A1 (enExample) |
| IL (2) | IL244258A0 (enExample) |
| MX (1) | MX373466B (enExample) |
| MY (1) | MY173548A (enExample) |
| PE (1) | PE20160877A1 (enExample) |
| RU (1) | RU2648144C2 (enExample) |
| SA (1) | SA516370751B1 (enExample) |
| SG (1) | SG11201601221XA (enExample) |
| TW (1) | TWI631134B (enExample) |
| WO (1) | WO2015044836A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1215196A1 (zh) | 2013-01-31 | 2016-08-19 | 辉瑞公司 | 用於抵消因子xa抑制的组合物和方法 |
| AU2014326257B2 (en) | 2013-09-24 | 2017-08-10 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins |
| PE20190661A1 (es) * | 2016-06-17 | 2019-05-08 | Portola Pharm Inc | Preparacion de derivados del factor xa |
| EP3722418A1 (en) * | 2019-04-08 | 2020-10-14 | AB Enzymes Oy | Solution stable enzyme composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
| AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
| AU2001249389A1 (en) | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
| FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| FR2841904B1 (fr) | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
| JP2008509688A (ja) * | 2004-08-17 | 2008-04-03 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 改変ビタミンｋ依存性ポリペプチド |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| MX336958B (es) | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| DK2915564T3 (da) * | 2007-09-28 | 2021-02-08 | Alexion Pharma Inc | Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf |
| AU2009264282B2 (en) | 2008-06-24 | 2013-04-18 | Octapharma Ag | A process of purifying coagulation factor VIII |
| JP5709316B2 (ja) | 2008-11-14 | 2015-04-30 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法 |
| US8436144B2 (en) | 2008-12-19 | 2013-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders |
| EP2453910B1 (en) * | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
| EA201291482A1 (ru) * | 2010-07-09 | 2013-10-30 | Байоджен Айдек Хемофилия Инк. | Химерные факторы коагуляции |
| FR2972114B1 (fr) | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
| AU2012315516B2 (en) | 2011-09-30 | 2017-05-04 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis |
| MX365612B (es) | 2012-07-25 | 2019-06-07 | Catalyst Biosciences Inc | Polipeptidos de factor x modificados y usos de los mismos. |
| HK1215196A1 (zh) | 2013-01-31 | 2016-08-19 | 辉瑞公司 | 用於抵消因子xa抑制的组合物和方法 |
| AU2014326257B2 (en) | 2013-09-24 | 2017-08-10 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins |
| CA2928762A1 (en) | 2013-11-01 | 2015-05-07 | The Children's Hospital Of Philadelphia | Compositions and methods for increasing the half-life of factor xa |
| MX375355B (es) | 2014-01-24 | 2025-03-04 | Pfizer | Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral. |
-
2014
- 2014-09-16 AU AU2014326257A patent/AU2014326257B2/en not_active Ceased
- 2014-09-16 BR BR112016005899A patent/BR112016005899A8/pt not_active IP Right Cessation
- 2014-09-16 CN CN201480052212.2A patent/CN105579468A/zh active Pending
- 2014-09-16 RU RU2016108608A patent/RU2648144C2/ru active
- 2014-09-16 HK HK16106674.2A patent/HK1218760A1/zh unknown
- 2014-09-16 KR KR1020167007373A patent/KR101988705B1/ko not_active Expired - Fee Related
- 2014-09-16 CN CN202011112690.1A patent/CN112195169A/zh active Pending
- 2014-09-16 EP EP14792595.2A patent/EP3049434A1/en not_active Withdrawn
- 2014-09-16 MY MYPI2016700985A patent/MY173548A/en unknown
- 2014-09-16 PE PE2016000398A patent/PE20160877A1/es unknown
- 2014-09-16 MX MX2016003871A patent/MX373466B/es active IP Right Grant
- 2014-09-16 CA CA2924981A patent/CA2924981C/en not_active Expired - Fee Related
- 2014-09-16 SG SG11201601221XA patent/SG11201601221XA/en unknown
- 2014-09-16 JP JP2016543477A patent/JP6429885B2/ja not_active Expired - Fee Related
- 2014-09-16 WO PCT/IB2014/064564 patent/WO2015044836A1/en not_active Ceased
- 2014-09-23 AR ARP140103512A patent/AR097732A1/es unknown
- 2014-09-23 TW TW103132803A patent/TWI631134B/zh not_active IP Right Cessation
- 2014-09-24 US US14/495,478 patent/US9757434B2/en not_active Expired - Fee Related
-
2016
- 2016-02-23 IL IL244258A patent/IL244258A0/en unknown
- 2016-03-17 SA SA516370751A patent/SA516370751B1/ar unknown
-
2017
- 2017-08-04 US US15/669,340 patent/US10660946B2/en active Active
-
2020
- 2020-05-25 US US16/882,598 patent/US20210106658A1/en not_active Abandoned
- 2020-12-13 IL IL279396A patent/IL279396A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016005899A8 (pt) | 2018-02-06 |
| KR20160044034A (ko) | 2016-04-22 |
| CN105579468A (zh) | 2016-05-11 |
| US20150182604A1 (en) | 2015-07-02 |
| TWI631134B (zh) | 2018-08-01 |
| AU2014326257A1 (en) | 2016-03-10 |
| IL244258A0 (en) | 2016-04-21 |
| BR112016005899A2 (pt) | 2017-09-26 |
| TW201524996A (zh) | 2015-07-01 |
| JP6429885B2 (ja) | 2018-11-28 |
| AU2014326257B2 (en) | 2017-08-10 |
| KR101988705B1 (ko) | 2019-06-12 |
| EP3049434A1 (en) | 2016-08-03 |
| CA2924981A1 (en) | 2015-04-02 |
| WO2015044836A1 (en) | 2015-04-02 |
| US20170333535A1 (en) | 2017-11-23 |
| MX2016003871A (es) | 2016-08-04 |
| RU2648144C2 (ru) | 2018-03-22 |
| IL279396A (en) | 2021-01-31 |
| PE20160877A1 (es) | 2016-09-11 |
| MX373466B (es) | 2020-05-25 |
| CA2924981C (en) | 2020-03-31 |
| MY173548A (en) | 2020-02-04 |
| RU2016108608A (ru) | 2017-10-26 |
| CN112195169A (zh) | 2021-01-08 |
| SG11201601221XA (en) | 2016-04-28 |
| US20210106658A1 (en) | 2021-04-15 |
| AR097732A1 (es) | 2016-04-13 |
| HK1218760A1 (zh) | 2017-03-10 |
| JP2016535071A (ja) | 2016-11-10 |
| US9757434B2 (en) | 2017-09-12 |
| US10660946B2 (en) | 2020-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Esmon et al. | Structure, assembly, and secretion of octameric invertase. | |
| RU2722374C1 (ru) | Высокогликозилированный слитый белок на основе фактора свертывания крови человека viii, способ его получения и его применение | |
| AU2021261911B2 (en) | Polypeptides modulating SIGLEC dependent immune responses | |
| EA012162B1 (ru) | Способ рефолдинга рекомбинантных антител | |
| NO321096B1 (no) | Fremgangsmate for forbedring av in vivo-funksjonen av rekombinant faktor VIII SQ ved a skjerme utsatte mal pa polypeptidet | |
| SA516370751B1 (ar) | تركيبات تشمل مجموعات متغايرة من بروتينات xa لعامل تخثر آدمي تخليقي | |
| ES2349112T3 (es) | Método de purificación de factor vii. | |
| CN111349142B (zh) | 一种蛋白质的纯化方法 | |
| US20250257347A1 (en) | Coagulation factor x activating enzyme and use thereof | |
| CN103814137A (zh) | 处理凝血因子的方法 | |
| Kittur et al. | Two-step purification procedure for recombinant human asialoerythropoietin expressed in transgenic plants | |
| HK40003560A (en) | Polypeptides modulating siglec dependent immune responses | |
| HK40003560B (en) | Polypeptides modulating siglec dependent immune responses |